Fuu-Jen Tsai

Dr. Fuu-Jen Tsai

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2020 in Nature
Verified
Journal Article
Closed access
PDF file
CSCassandra N. Spracklen
Cassandra N. Spracklen
MHMomoko Horikoshi
Momoko Horikoshi
YKYoung Jin Kim
Young Jin Kim
KLKuang Lin
Kuang Lin
FBFiona Bragg
Fiona Bragg
XSXueling Sim
Xueling Sim

19 May 2021 in Journal of Food Biochemistry
Verified
Journal Article
Closed access
PDF file
WCWen‐Shin Chang
Wen‐Shin Chang
CTChia‐Wen Tsai
Chia‐Wen Tsai
JYJai-Sing Yang
Jai-Sing Yang
YHYuan‐Man Hsu
Yuan‐Man Hsu
LSLiang‐Chun Shih
Liang‐Chun Shih
FTFuu-Jen Tsai
Fuu-Jen Tsai

28 May 2019 in Nutrition & Metabolism
Verified
Journal Article
Open access
PDF file
KWKuen-Ming Wu
Kuen-Ming Wu
YHYuan-Man Hsu
Yuan-Man Hsu
MYMei-chin Yin
Mei-chin Yin
FTFuu-Jen Tsai
Fuu-Jen Tsai
CTChang-Hai Tsai
Chang-Hai Tsai
CHChih-Yang Huang
Chih-Yang Huang
High levels circulating saturated fatty acids are associated with diabetes, obesity and hyperlipidemia. In heart, the accumulation of saturated fatty acids has been determined to play a role in the development of heart failure and diabetic cardiomyopathy. High-density lipoprotein (HDL) has been reported to possess key atheroprotective biological properties, including cellular cholesterol efflux capacity, anti-oxidative and anti-inflammatory activities. However, the underlying mechanisms are still largely unknown. Therefore, the aim of the present study is to test whether HDL could protect palmitic acid (PA)-induced cardiomyocyte injury and explore the possible mechanisms. H9c2 cells were pretreated with HDL (50–100 μg/ml) for 2 h followed by PA (0.5 mM) for indicated time period. Our results showed that HDL inhibited PA-induced cell death in a dose-dependent manner. Moreover, HDL rescued PA-induced ROS generation and the phosphorylation of JNK which in turn activated NF-κB-mediated inflammatory proteins expressions. We also found that PA impaired the balance of BCL2 family proteins, destabilized mitochondrial membrane potential, and triggered subsequent cytochrome c release into the cytosol and activation of caspase 3. These detrimental effects were ameliorated by HDL treatment. PA-induced ROS accumulation and results in cardiomyocyte apoptosis and inflammation. However, HDL attenuated PA-induced lipotoxicity and oxidative dysfunction via ROS suppression. These results may provide insight into a possible molecular mechanism underlying HDL suppression of the free fatty acid-induced cardiomyocyte apoptosis.

14 June 2017 in BioMedicine
Verified
Journal Article
Open access
PDF file
JYJai-Sing Yang
Jai-Sing Yang
CLChi-Cheng Lu
Chi-Cheng Lu
SKSheng-Chu Kuo
Sheng-Chu Kuo
YHYuan-Man Hsu
Yuan-Man Hsu
STShih-Chang Tsai
Shih-Chang Tsai
FTFuu-Jen Tsai
Fuu-Jen Tsai
Autophagy, a double-edged sword for cell survival, is the research object on 2016 Nobel Prize in Physiology or Medicine. Autophagy is a molecular mechanism for maintaining cellular physiology and promoting survival. Defects in autophagy lead to the etiology of many diseases, including diabetes mellitus (DM), cancer, neurodegeneration, infection disease and aging. DM is a metabolic and chronic disorder and has a higher prevalence in the world as well as in Taiwan. The character of diabetes mellitus is hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance and failure of producing insulin on pancreatic beta cells. In T2DM, autophagy is not only providing nutrients to maintain cellular energy during fasting, but also removes damaged organelles, lipids and miss-folded proteins. In addition, autophagy plays an important role in pancreatic beta cell dysfunction and insulin resistance. In this review, we summarize the roles of autophagy in T2DM.

9 July 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
EHEddie T. C. Huang
Eddie T. C. Huang
JYJai-Sing Yang
Jai-Sing Yang
KLKen Y. K. Liao
Ken Y. K. Liao
WTWarren C. W. Tseng
Warren C. W. Tseng
CLC. K. Lee
C. K. Lee
FTFuu-Jen Tsai
Fuu-Jen Tsai
Predicting the blood–brain barrier (BBB) permeability of small-molecule compounds using a novel artificial intelligence platform is necessary for drug discovery. Machine learning and a large language model on artificial intelligence (AI) tools improve the accuracy and shorten the time for new drug development. The primary goal of this research is to develop artificial intelligence (AI) computing models and novel deep learning architectures capable of predicting whether molecules can permeate the human blood–brain barrier (BBB). The in silico (computational) and in vitro (experimental) results were validated by the Natural Products Research Laboratories (NPRL) at China Medical University Hospital (CMUH). The transformer-based MegaMolBART was used as the simplified molecular input line entry system (SMILES) encoder with an XGBoost classifier as an in silico method to check if a molecule could cross through the BBB. We used Morgan or Circular fingerprints to apply the Morgan algorithm to a set of atomic invariants as a baseline encoder also with an XGBoost classifier to compare the results. BBB permeability was assessed in vitro using three-dimensional (3D) human BBB spheroids (human brain microvascular endothelial cells, brain vascular pericytes, and astrocytes). Using multiple BBB databases, the results of the final in silico transformer and XGBoost model achieved an area under the receiver operating characteristic curve of 0.88 on the held-out test dataset. Temozolomide (TMZ) and 21 randomly selected BBB permeable compounds (Pred scores = 1, indicating BBB-permeable) from the NPRL penetrated human BBB spheroid cells. No evidence suggests that ferulic acid or five BBB-impermeable compounds (Pred scores < 1.29423E−05, which designate compounds that pass through the human BBB) can pass through the spheroid cells of the BBB. Our validation of in vitro experiments indicated that the in silico prediction of small-molecule permeation in the BBB model is accurate. Transformer-based models like MegaMolBART, leveraging the SMILES representations of molecules, show great promise for applications in new drug discovery. These models have the potential to accelerate the development of novel targeted treatments for disorders of the central nervous system.

14 June 2017 in BioMedicine
Verified
Journal Article
Open access
PDF file
MLMiau-Rong Lee
Miau-Rong Lee
CLChingju Lin
Chingju Lin
CLChi-Cheng Lu
Chi-Cheng Lu
SKSheng-Chu Kuo
Sheng-Chu Kuo
JTJe-Wei Tsao
Je-Wei Tsao
FTFuu-Jen Tsai
Fuu-Jen Tsai
Oral cancer is a serious and fatal disease. Cisplatin is the first line of chemotherapeutic agent for oral cancer therapy. However, the development of drug resistance and severe side effects cause tremendous problems clinically. In this study, we investigated the pharmacologic mechanisms of YC-1 on cisplatin-resistant human oral cancer cell line, CAR. Our results indicated that YC-1 induced a concentration-dependent and time-dependent decrease in viability of CAR cells analyzed by MTT assay. Real-time image analysis of CAR cells by IncuCyte™ Kinetic Live Cell Imaging System demonstrated that YC-1 inhibited cell proliferation and reduced cell confluence in a time-dependent manner. Results from flow cytometric analysis revealed that YC-1 promoted G0/G1 phase arrest and provoked apoptosis in CAR cells. The effects of cell cycle arrest by YC-1 were further supported by up-regulation of p21 and down-regulation of cyclin A, D, E and CDK2 protein levels. TUNEL staining showed that YC-1 caused DNA fragmentation, a late stage feature of apoptosis. In addition, YC-1 increased the activities of caspase-9 and caspase-3, disrupted the mitochondrial membrane potential (AYm) and stimulated ROS production in CAR cells. The protein levels of cytochrome c, Bax and Bak were elevated while Bcl-2 protein expression was attenuated in YC-1-treated CAR cells. In summary, YC-1 suppressed the viability of cisplatin-resistant CAR cells through inhibiting cell proliferation, arresting cell cycle at G0/G1 phase and triggering mitochondria-mediated apoptosis. Our results provide evidences to support the potentially therapeutic application of YC-1 on fighting against drug resistant oral cancer in the future.